Ken Griffin’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Ken Griffin’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-57,801	Closed	-$580K	–	15786
2023 Q4	$580K	Buy	+57,801	New	+$262K	﹤0.01%	7766
2022 Q2	–	Sell	-54,383	Closed	-$126K	–	14468
2022 Q1	$126K	Buy	+54,383	New	+$185K	﹤0.01%	12042
2021 Q4	–	Sell	-17,514	Closed	-$243K	–	15056
2021 Q3	$243K	Sell	17,514 -22,948	-57%	-$271K	﹤0.01%	11542
2021 Q2	$526K	Buy	40,462 +1,763	+5%	+$23.6K	﹤0.01%	9953
2021 Q1	$596K	Buy	+38,699	New	+$913K	﹤0.01%	9302

Ken Griffin's GRCL Position: Q1 2024 in Review

Ken Griffin sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 57,801 shares — an estimated $580K sold.

Ken Griffin first reported a position in GRCL in Q1 2021 and held it in 5 quarters. The position peaked at $596K in Q1 2021. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Ken Griffin reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Ken Griffin sold 57,801 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $580K.
Ken Griffin first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 5 quarters.
Ken Griffin's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $596K in Q1 2021.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.